Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1)

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Spadaro, Alessandro ^a,b   Negri, Matthias ^c   Marchais Oberwinkler, Sandrine ^a   Bey, Emmanuel ^b   Frotscher, Martin ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ElexoPharm GmbH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOTHIAZOLE DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; OXIDOREDUCTASE INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 1 INHIBITOR; TESTOSTERONE 17BETA DEHYDROGENASE TYPE 2; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ESTROGEN; HYDROXYSTEROID DEHYDROGENASE; LIGAND; THIAZOLE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL FREE SYSTEM; CHEMICAL MODIFICATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; IC 50; MOLECULAR INTERACTION; PHARMACOPHORE; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLIZATION; DRUG ANTAGONISM; HUMAN; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

17-HYDROXYSTEROID DEHYDROGENASES; CELL LINE, TUMOR; CRYSTALLIZATION; ENZYME INHIBITORS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGENS, NON-STEROIDAL; HUMANS; LIGANDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84855398790     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029252     Document Type: Article

References (79)

1. Ferin M, Zimmering PE, Liebrman S, Vande Wiele RL, (1968) Inactivation of the biological effects of exogenous and endogenous estrogens by antibodies to 17β-Estradiol. Endocrinology 83: 565-571.
2. Jeon GH, Kim SH, Yun SC, Chae HD, Kim CH, et al. (2010) Association between serum estradiol level and coronary artery calcification in postmenopausal women. Menopause 17: 902-907.
3. Imai Y, Youn MY, Kondoh S, Nakamura T, Kouzmenko A, et al. (2009) Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann NY Acad Sci 1173: (Suppl 1): E31-E39.
4. National Cancer Institute (NCI) (2006) Understanding cancer series: estrogen receptors/SERMs. web site: http://cancer.gov/cancertopics/understandingcancer.
5. Liehr JG, (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21: 40-54.
6. Hall JM, Couse JF, Korach KS, (2001) The multifaceted mechanisms of estradiol and estrogen receptor signalling. J Biol Chem 276: 36869-36872.
7. Thomas DB, (1984) Do hormones cause breast cancer? Cancer 53: 595-604.
8. Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, et al. (2006) 17beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells. FASEB J 20: 1622-1634.
9. Dizerega GS, Barber DL, Hodgen GD, (1980) Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression. Fertil Steril 33: 649-653.
10. Zeitoun K, Takayama K, Sasano H, Suzuki T, Moghrabi N, et al. (1998) Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metab 83: 4474-4480.
11. Cavalli A, Bisi A, Bertucci C, Rosini C, Paluszcak A, et al. (2005) Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem 48: 7282-7289.
12. Le Borgne M, Marchand P, Duflos M, Delevoye-Seiller B, Piessard-Robert S, et al. (1997) Synthesis and in vitro evaluation of 3-(1-azolylmethyl)-1Hindoles and 3-(1-azolyl-1-phenylmethyl)-1H-indoles as inhibitors of P450 arom. Arch Pharm (Weinheim) 330: 141-145.
13. Jacobs C, Frotscher M, Dannhardt G, Hartmann RW, (2000) 1-imidazolyl(alkyl)-substituted di- and tetrahydroquinolines and analogues: syntheses and evaluation of dual inhibitors of thromboxane A(2) synthase and aromatase. J Med Chem 43: 1841-1851.
14. Janni W, Hepp P, (2010) Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 36: 249-261.
15. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135-1141.
16. Tonezzer T, Pereira CM, Filho UP, Marx A, (2010) Hormone therapy/adjuvant chemotherapy induced deleterious effects on the bone mass of breast cancer patients and the intervention of physiotherapy: a literature review. Eur J Gynaecol Oncol 31: 262-267.
17. Baston E, Hartmann RW, (1999) N-substituted 4-(5-indolyl)benzoic acids. Synthesis and evaluation of steroid 5alpha-reductase type I and II inhibitory activity. Bioorg Med Chem Lett 9: 1601-1606.
18. Picard F, Baston E, Reichert W, Hartmann RW, (2000) Synthesis of N-substituted piperidine-4-(benzylidene-4-carboxylic acids) and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2. Bioorg Med Chem 8: 1479-1487.
19. Picard F, Schulz T, Hartmann RW, (2002) 5-Phenyl substituted 1-methyl-2-pyridones and 4′-substituted biphenyl-4-carboxylic acids: synthesis and evaluation as inhibitors of steroid-5alpha-reductase type 1 and 2. Bioorg Med Chem 10: 437-448.
20. Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M, (2010) An overview on 5alphareductase inhibitors. Steroids 75: 109-153.
21. Baston E, Palusczak A, Hartmann RW, (2000) 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: synthesis and evaluation as inhibitors of steroid 5α reductases types 1 and 2. Eur J Med Chem 35: 931-940.
22. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M, et al. (2000) 17beta-hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 82: 518-523.
23. Speirs V, Green AR, Atkin SL, (1998) Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8. J Steroid Biochem Mol Biol 67: 267-274.
24. Gunnarsson C, Ahnström M, Kirschner K, Olsson B, Nordenskjöld B, et al. (2003) Amplification of HSD17B1 and ERBB2 in primary breast cancer. Oncogene 22: 34-40.
25. Šmuc T, Hevir N, Pucelj Ribič M, Husen B, Thole H, et al. (2009) Disturbed estrogen and progesterone action in ovarian endometriosis. Mol Cell Endocrinol 301: 59-64.
26. Husen B, Huhtinen K, Poutanen M, Kangas L, Messinger J, et al. (2006) Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol 248: 109-113.
27. Husen B, Huhtinen K, Saloniemi T, Messinger J, Thole HH, et al. (2006) Human hydroxysteroid (17beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 147: 5333-5339.
28. Day JM, Foster PA, Tutill HJ, Parsons MFC, Newman SP, et al. (2008) 17betahydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 122: 1931-1940.
29. Laplante Y, Cadot C, Fournier MA, Poirier D, (2008) Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg Med Chem 16: 1849-1860.
30. Kruchten P, Werth R, Bey E, Oster A, Marchais-Oberwinkler S, et al. (2009) Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17betaHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. J Steroid Biochem Mol Biol 114: 200-206.
31. Xu K, Wetzel M, Hartmann RW, Marchais-Oberwinkler S, (2011) Synthesis and biological evaluation of spiro-δ-lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2). Lett Drug Disc Des 8: 406-421.
32. Wetzel M, Marchais-Oberwinkler S, Hartmann RW, (2011) 17β-HSD2 inhibitors for the treatment of osteoporosis. Identification of a promising scaffold. Bioorg Med Chem 19: 807-815.
33. Poirier D, (2003) Inhibitors of 17 beta-hydroxysteroid dehydrogenases. Curr Med Chem 10: 453-477.
34. Day JM, Tutill HJ, Purohit A, Reed MJ, (2008) Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 15: 665-692.
35. Brožic P, Lanišnik Rižner T, Gobec S, (2008) Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr Med Chem 15: 137-150.
36. Poirier D, (2009) Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. Anticancer Agents Med Chem 9: 642-660.
37. Poirier D, (2010) 17beta-Hydroxysteroid dehydrogenase inhibitors: a patent review. Expert Opin Ther Pat 20: 1123-1145.
38. Day JM, Tutill HJ, Purohit A, (2010) 17β-Hydroxysteroid dehydrogenase inhibitors. Minerva Endocrinol 35: 87-108.
39. Marchais-Oberwinkler S, Henn C, Möller G, Klein T, Negri M, et al. (2011) 17β-Hydroxysteroid dehydrogenases (17β-HSDs) as therapeutic targets: protein structures, functions, and recent progress in inhibitor development. J Steroid Biochem Mol Biol 125: 66-82.
40. Messinger J, Hirvelä L, Husen B, Kangas L, Koskimies P, et al. (2006) New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 248: 192-198.
41. Allan GM, Vicker N, Lawrence HR, Tutill HJ, Day JM, et al. (2008) Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. Bioorg Med Chem 16: 4438-4456.
42. Karkola S, Lilienkampf A, Wähälä K, (2008) A 3D QSAR model of 17beta-HSD1 inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core applying molecular dynamics simulations and ligand-protein docking. Chem Med Chem 3: 461-472.
43. Schuster D, Nashev LG, Kirchmair J, Laggner C, Wolber G, et al. (2008) Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J Med Chem 51: 4188-4199.
44. Brozic P, Kocbek P, Sova M, Kristl J, Martens S, et al. (2009) Flavonoids and cinnamic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 301: 229-234.
45. Lilienkampf A, Karkola S, Alho-Richmond S, Koskimies P, Johansson N, et al. (2009) Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core. J Med Chem 52: 6660-6671.
46. Starčević S, Brožič P, Turk S, Cesar J, Lanišnik Rižner T, et al. (2011) Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1. J Med Chem 54: 248-261.
47. Starčević S, Turk S, Brus B, Cesar J, Lanišnik Rižner T, et al. (2011) Discovery of highly potent, nonsteroidal 17β-hydroxysteroid dehydrogenase type 1 inhibitors by virtual high-throughput screening. J Steroid Biochem Mol Biol doi:10.1016/j.jsbmb.2011.08.013.
48. Bey E, Marchais-Oberwinkler S, Kruchten P, Frotscher M, Werth R, et al. (2008) Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17betahydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bioorg Med Chem 16: 6423-6435.
49. Bey E, Marchais-Oberwinkler S, Werth R, Negri M, Al-Soud YA, et al. (2008) Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem 51: 6725-6739.
50. Al-Soud YA, Bey E, Oster A, Marchais-Oberwinkler S, Werth R, et al. (2009) The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17beta-Hydroxysteroid Dehydrogenase (17beta-HSD) type 1 and type 2. Mol Cell Endocrinol 301: 212-215.
51. Bey E, Marchais-Oberwinkler S, Negri M, Kruchten P, Oster A, et al. (2009) New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and-benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. J Med Chem 52: 6724-6743.
52. Oster A, Klein T, Werth R, Kruchten P, Bey E, et al. (2010) Novel estrone mimetics with high 17beta-HSD1 inhibitory activity. Bioorg Med Chem 18: 3494-3505.
53. Oster A, Hinsberger S, Werth R, Marchais-Oberwinkler S, Frotscher M, et al. (2010) Bicyclic substituted hydroxyphenylmethanones as novel inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem 53: 8176-8186.
54. Frotscher M, Ziegler E, Marchais-Oberwinkler S, Kruchten P, Neugebauer A, et al. (2008) Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and-quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem 51: 2158-2169.
55. Marchais-Oberwinkler S, Kruchten P, Frotscher M, Ziegler E, Neugebauer A, et al. (2008) Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. J Med Chem 51: 4685-4698.
56. Marchais-Oberwinkler S, Frotscher M, Ziegler E, Werth R, Kruchten P, et al. (2009) Structure-activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors. Mol Cell Endocrinol 301: 205-211.
57. Marchais-Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, et al. (2010) New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17β-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases. J Med Chem 54: 534-547.
58. Oster A, Klein T, Henn C, Werth R, Marchais-Oberwinkler S, et al. (2011) Bicyclic substituted hydroxyphenylmethanone type inhibitors of 17β-hydroxysteroid dehydrogenase Type 1 (17β-HSD1): the role of the bicyclic moiety. Chem Med Chem 6: 476-487.
59. Kruchten P, Werth R, Marchais-Oberwinkler S, Frotscher M, Hartmann RW, (2009) Development of a biological screening system for the evaluation of highly active and selective 17beta-HSD1-inhibitors as potential therapeutic agents. Mol Cell Endocrinol 301: 154-157.
60. Negri M, Recanatini M, Hartmann RW, (2010) Insights in 17β-HSD1 enzyme kinetics and ligand binding by dynamic motion investigation. PLoS ONE 5 (8): e12026 doi:10.1371/journal.pone.0012026.
61. Mazza C, (1997) Human type 1 17 beta-hydroxysteroid dehydrogenase: site directed mutagenesis and x-ray crystallography structure-function analysis. DOI:10.2210/pdb1a27/pdb.
62. Sawicki MW, Erman M, Puranen T, Vihko P, Ghosh D, (1999) Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+. Proc Natl Acad Sci USA 96: 840-845.
63. Han Q, Campbell RL, Gangloff A, Huang YW, Lin SX, (2000) Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17betahydroxysteroid dehydrogenase. C-18/C19 steroid discrimination and enzymeinduced strain. J Biol Chem 275: 1105-1111.
64. Qiu W, Campbell RL, Gangloff A, Dupuis P, Boivin RP, et al. (2002) A concerted, rational design of type 1 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrids with high affinity. Faseb J 16: 1829-1831.
65. Mazumdar M, Fournier D, Zhu DW, Cadot C, Poirier D, et al. (2009) Binary and ternary crystal structure analyses of a novel inhibitor with 17β-HSD type 1: a lead compound for breast cancer therapy. Biochem J 424: 357-366.
66. Cabedo N, Andreu I, Ramírez de Arellano MC, Chagraoui A, Serrano A, et al. (2001) Enantioselective syntheses of dopaminergic (R)- and (S)-Benzyltetrahydroisoquinolines. J Med Chem 44: 1794-1801.
67. Chikashita H, Ishibaba M, Ori K, Itoh K, (1988) General reactivity of 2-lithiobenzothiazole to various electrophiles and the use as a formyl anion equivalent in the synthesis of a-hydroxy carbonyl compounds. Bull Chem Soc Jpn 61: 3637-3648.
68. Tang G, Nikolovska-Coleska Z, Qiu S, Yang CY, Guo J, et al. (2008) Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. J Med Chem 51: 717-720.
69. Nelson TD, Crouch RD, (1996) Selective deprotection of silyl ethers. Synthesis 9: 1031-1069.
70. Chedekel MR, Sharp DE, Jeffery GA, (1980) Synthesis of o-aminothiophenols. Synth Commun 10: 167-173.
71. Stoner EJ, Cothron DA, Balmer MK, Roden BA, (1995) Benzylation via tandem grignard reaction- iodotrimethylsilane (TMSI) mediated reduction. Tetrahedron 51: 11043-11062.
72. Kim KS, Kimball SD, Misra RN, Rawlins DB, Hunt JT, et al. (2002) Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 45: 3905-3927.
73. Jansson A, Gunnarsson C, Stål O, (2006) Proliferative responses to altered 17beta-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr Relat Cancer 13: 875-884.
74. Kagechika H, Himi T, Kawachi E, Shudo K, (1989) Retinobenzoic acids. 4. Conformation of aromatic amides with retinoidal activity. Importance of trans-amide structure for the activity. J Med Chem 32: 2292-2296.
75. Alho-Richmond S, Lilienkampf A, Wähälä K, (2006) Active site analysis of 17β-hydroxysteroid dehydrogenase type 1 enzyme complexes with SPROUT. Mol Cell Endocrinol 248: 208-213.
76. Gangloff A, Garneau A, Huang YW, Yang F, Lin SX, (2001) Human oestrogenic 17beta-hydroxysteroid dehydrogenase specificity: enzyme regulation through an NADPH-dependent substrate inhibition towards the highly specific oestrone reduction. Biochem J 356: 269-276.
77. Puranen TJ, Kurkela RM, Lakkakorpi JT, Poutanen MH, Itäranta PV, et al. (1999) Characterization of molecular and catalytic properties of intact and truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. Endocrinology 140: 3334-3341.
78. Pillon A, Boussioux A, Escande A, Aït-Aïssa S, Gomez E, et al. (2005) Binding of estrogenic compounds to recombinant estrogen receptor-alpha: application to environmental analysis. Environ Health Perspect 113: 278-284.
79. Zhu BT, Han G, Shim J, Wen Y, Jiang X, (2006) Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology 147: 4132-4150.